DRIVE for Health Equity: Tailoring Quality Improvement, Clinical Education, and Community Engagement to Improve Type 2 Diabetes (T2DM) Outcomes for Minoritized Communities in Oakland, California
Main Article Content
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) is influenced by various factors, with racial and ethnic minorities experiencing higher prevalence. Existing diabetes management programs focus on primary prevention, often neglecting optimal hemoglobin A1C (HbA1c) management for individuals with prediabetes. Consistent HbA1c monitoring is crucial for comprehensive care. This study highlighted the need for secondary prevention and community collaboration to enhance health equity for individuals with T2DM.
The DRIVE program, conducted by the National Minority Quality Forum's (NMQF) Center for Sustainable Health Care Quality and Equity (SHC), aimed to improve health outcomes for individuals with Type 2 Diabetes Mellitus (T2DM) in Oakland, CA. Building on prior successes in New Orleans, Los Angeles, and Queens, NY, DRIVE employs a flexible and sustainable approach that integrates quality improvement strategies at clinic sites, focusing on patient and community engagement. The study addressed barriers to medication adherence, provided Diabetes Self-Management Education and Support (DSMES), fostered community partnerships, and utilized culturally appropriate resources. The program's impact was evaluated through changes in HbA1c levels and community participation.
Methods: A pre-and post-test design was used, targeting patients of Baywell Health, Oakland, CA, aged 18 and older with initial HbA1c levels greater than 9%. The intervention, developed using SHC’s DRIVE program, included components such as food distribution events, workflow enhancements, identification and mitigation of medication adherence barriers, rapid cycle improvement processes, community educational sessions, and the creation of patient resources. This two-year study implemented four Plan-Do-Study-Act (PDSA) cycles, each lasting 2-4 months, following a three-month planning phase. HbA1c levels were measured at baseline, six months after implementation, and again at 18-month follow-up.
Statistical Analysis
Univariate analyses described demographic data, while paired sample t-tests assessed changes in HbA1c levels. Independent sample t-tests and ANOVA with pairwise comparisons were used to determine group differences.
Results: Among the 255 participants, 58% identified as female and 42% as male. The majority were Black/African American (64%) and 73% were Non-Hispanic/Latino/a, with a mean age of 55.4 years. HbA1c levels were significantly reduced from an average of 10.3±1.4 to 9.4±2.1 at follow-up. Participants who enrolled the longest showed greater reductions. Community initiatives reached over 600 individuals, demonstrating the program's effectiveness in building partnerships and sustainability.
Conclusion: SHC’s DRIVE program improved T2DM outcomes through community involvement, quality improvement, and culturally tailored education. This initiative highlighted the importance of addressing health inequities and barriers in diabetes care through culturally sensitive techniques and sustained interventions. DRIVE effectively reduced disparities and promoted sustainable health outcomes among minority groups. Collaborative efforts enhanced trust and demonstrated the advancement of health equity through tailored interventions, with DRIVE providing a flexible and sustainable framework for tailoring interventions to community needs. These findings underscored the need for individualized, culturally competent diabetes care, continuous education, community engagement, and equitable resource access to support communities of color and ethnic minorities in managing T2DM effectively.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Zalan A, Sharkia R. T2DM Mellitus (T2DM) in the Arab Society of Israel. Handbook of Healthcare in the Arab World: Springer; 2021. p. 1101-31. https://doi.org/10.1007/978-3-030-36811-1_162
3. Olokoba AB, Obateru OA, Olokoba LB. T2DM mellitus: a review of current trends. Oman medical journal. 2012;27(4):269. https://doi.org/10.5001%2Fomj.2012.68
4. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of T2DM. Diabetes. 2002;51(10):3120-7. https://doi.org/10.2337/diabetes.51.10.3120
5. Rachdaoui N. Insulin: the friend and the foe in the development of T2DM mellitus. International journal of molecular sciences. 2020;21(5):1770. https://doi.org/10.3390/ijms21051770
6. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of T2DM mellitus—present and future perspectives. Nature reviews endocrinology. 2012;8(4):228-36. https://doi.org/10.1038/nrendo.2011.183
7. Smolen J, Burmester G, Combeet B. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants. Lancet 2016; 387: 1513–30. https://doi.org/10.1016/S0140-6736(16)32060-8
8. Malenfant JH, Batsis JA. Obesity in the geriatric population–a global health perspective. Journal of global health reports. 2019;3. https://doi.org/10.29392%2Fjoghr.3.e2019045
9. Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and T2DM. Current cardiology reports. 2019;21:1-7. https://doi.org/10.1007/s11886-019-1133-9
10. Gæde P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with T2DM. New England Journal of Medicine. 2003;348(5):383-93. doi:10.1056/NEJMoa021778
11. Cho NH, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271-81. https://doi.org/10.1016/j.diabres.2018.02.02
12. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. The Lancet. 2012;379(9833):2252-61. https://doi.org/10.1016/S0140-6736(12)60480-2
13. Lucero JE, Roubideaux Y. Advancing diabetes prevention and control in American Indians and Alaska Natives. Annual review of public health. 2022;43:461-75. https://doi.org/10.1146/annurev-publhealth-093019-010011
14. Fang M. Trends in the prevalence of diabetes among US adults: 1999–2016. American journal of preventive medicine. 2018;55(4):497-505. https://doi.org/10.1016/j.amepre.2018.05.018
15. Richmond CA, Ross NA. The determinants of First Nation and Inuit health: A critical population health approach. Health & place. 2009;15(2):403-11. https://doi.org/10.1016/j.healthplace.2008.07.004
16. Catherine H, Zinman B. T2DM and impaired glucose tolerance in aboriginal populations: a global perspective. Diabetes research and clinical practice. 2007;78(2):159-70. https://doi.org/10.1016/j.diabres.2007.03.022
17. Gracey M, King M. Indigenous health part 1: determinants and disease patterns. The Lancet. 2009;374(9683):65-75. https://doi.org/10.1016/S0140-6736(09)60914-4
18. Swihart DL, Yarrarapu SNS, Martin RL. Cultural Religious Competence in Clinical Practice. Treasure Island (FL): StatPearls.Accessed June 24, 2024. https://www.ncbi.nlm.nih.gov/books/NBK493216/
19. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health And Nutrition Examination Survey 1999–2002. Diabetes care. 2006;29(6):1263-8. https://doi.org/10.2337/dc06-0062
20. Egede LE, Dagogo-Jack S. Epidemiology of T2DM: focus on ethnic minorities. Medical Clinics. 2005;89(5):949-75. https://doi.org/10.1016/j.mcna.2005.03.004
21. Kirk JK, D’Agostino Jr RB, Bell RA, Passmore LV, Bonds DE, Karter AJ, et al. Disparities in HbHbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes care. 2006;29(9):2130-6. https://doi.org/10.2337/dc05-1973
22. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with T2DM. Diabetes care. 2001;24(3):454-9. https://doi.org/10.2337/diacare.24.3.454
23. Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA internal medicine. 2017;177(12):1808-17. Doi:10.1001/jamainternmed.2017.6040
24. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Current diabetes reports. 2013;13:814-23. https://doi.org/10.1007/s11892-013-0421-9
25. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and T2DM among youths, 2002–2012. New England Journal of Medicine.2017;376(15):1419-29. doi: 10.1056/NEJMoa1610187
26. Alderwick H, Gottlieb LM. Meanings and misunderstandings: a social determinants of health lexicon for health care systems. The Milbank Quarterly. 2019;97(2):407. https://doi.org/10.1111%2F1468-0009.12390
27. Sandhu S, Sharma A, Cholera R, Bettger JP. Integrated health and social care in the United States: a decade of policy progress. International Journal of Integrated Care. 2021;21(4). https://doi.org/10.5334%2Fijic.5687
28. Saulsberry L, Gunter KE, O’Neal Y, Tanumihardjo J, Gauthier R, Chin MH, et al. “Everything in One Place”: Stakeholder Perceptions of Integrated Medical and Social Care for Diabetes Patients in Western Maryland. Journal of General Internal Medicine. 2023;38(Suppl 1):25-32. https://doi.org/10.1007/s11606-022-07919-1
29. Kannarkat JT, Hartle JE, Parekh N. Need for payer-provider partnerships in addressing social determinants of health. Journal of Managed Care & Specialty Pharmacy. 2021;27(6):791-6. https://doi.org/10.18553/jmcp.2021.27.6.791
30. Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health affairs. 2013;32(2):207-14. https://doi.org/10.1377/hlthaff.2012.1061
31. Harvey L, Fowles JB, Xi M, Terry P. When activation changes, what else changes? The relationship between change in patient activation measure (PAM) and employees’ health status and health behaviors. Patient education and counseling. 2012;88(2):338-43. https://doi.org/10.1016/j.pec.2012.02.005
32. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Springer; 2010. https://doi.org/10.1007/s13340-010-0006-7
33. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116(2):151-7. https://doi.org/10.1161/circulationaha.106.685628
34. Ackermann RT, Marrero DG. Adapting the diabetes prevention program lifestyle intervention for delivery in the community. The Diabetes Educator. 2007;33(1):69-78. https://doi.org/10.1177/0145721706297743
35. Perez M, Findley SE, Mejia M, Martinez J. The impact of community health worker training and programs in NYC. Journal of Health Care for the Poor and Underserved. 2006;17(1):26-43. https://doi.org/10.1353/hpu.2006.0049
36. Doss K. A study to assess the knowledge and attitude regarding self care activities among the patients with diabetes mellitus in selected hospitals at Coimbatore. Asian Journal of Nursing Education and Research. 2020;10(2):217-218. http://dx.doi.org/10.5958/2349-2996.2020.00046.4
37. Spencer MS, Rosland A-M, Kieffer EC, et al. Effectiveness of a community health worker intervention among African American and Latino adults with T2DM: a randomized controlled trial. American journal of public health. 2011;101(12):2253-2260. https://doi.org/10.2105/AJPH.2010.300106
38. Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes care. 2021;44(1):258. https://doi.org/10.2337%2Fdci20-0053
39. Schillinger D, Bullock A, Powell C, et al. The National Clinical Care Commission report to Congress: leveraging federal policies and programs for population-level diabetes prevention and control: recommendations from the National Clinical Care Commission. Diabetes Care. 2023;46(2):e24-e38. https://doi.org/10.2337/dc22-0619
40. Meza R, Barrientos-Gutierrez T, Rojas-Martinez R, Reynoso-Noverón N, Palacio-Mejia LS, Lazcano-Ponce E, et al. Burden of T2DM in Mexico: past, current and future prevalence and incidence rates. Preventive medicine. 2015;81:445-450. https://doi.org/10.1016/j.ypmed.2015.10.015
41. Watkins YJ, Quinn LT, Ruggiero L, Quinn MT, Choi Y-K. Spiritual and religious beliefs and practices and social support’s relationship to diabetes self-care activities in African Americans. The Diabetes Educator. 2013;39(2):231-239. https://doi.org/10.1177/0145721713475843
42. Sankaran S. Health Equity in Hospital Medicine. Springer; 2024. https://doi.org/10.1007/978-3-031-44999-4
43. Addala A, Mungmode A, Ospelt E, Ochoa-Maya M, Zupa M, Ebekozien O, et al. Current Practices in Operationalizing and Addressing Racial Equity in the Provision of Type 1 Diabetes Care: Insights from the Type 1 Diabetes Exchange Quality Improvement Collaborative Health Equity Advancement Lab. Endocrine Practice. 2024;30(1):41-48. https://doi.org/10.1016/j.eprac.2023.10.001